drugset / Trial / NCT02194296

Relative Bioavailability of Ambroxol Hydrochloride Lozenge in Comparison to Ambroxol Hydrochloride Syrup (Mucosolvan®) in Healthy Female and Male Volunteers

NCT02194296

Phase 1 Completed 20 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to investigate the relative bioavailability of a 20 mg ambroxol hydrochloride lozenge compared to 30 mg ambroxol hydrochloride syrup (Mucosolvan®) after dose normalisation

Timeline

Start
1999-06
Primary completion
1999-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ambroxol Small molecule 20 mg
Comparator Ambroxol Small molecule 30 mg

Indications

No indication recorded.